Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: DANAHER

Market Cap 128B 110B 102B 95.38B 179B 12,114B 181B 1,202B 470B 5,932B 481B 471B 20,527B P/E Ratio 2026 *
28.9x
P/E Ratio 2027 * 22.9x
Enterprise Value 137B 118B 109B 102B 192B 12,967B 194B 1,287B 503B 6,350B 515B 504B 21,972B EV / Sales 2026 *
5.25x
EV / Sales 2027 * 4.66x
Free-Float
71.13%
Yield 2026 *
0.79%
Yield 2027 * 0.85%
Manager TitleAgeSince
Chief Executive Officer 62 2020-08-31
Director of Finance/CFO - 2026-02-27
Chief Tech/Sci/R&D Officer - 2025-08-24
Director TitleAgeSince
Director/Board Member 74 1999-06-30
Chairman 74 1983-12-31
Director/Board Member 69 1983-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-1.98% - - 128B
+0.38%-4.00%+17.09%-11.72% 176B
+0.53%-1.59%-19.12%+27.47% 148B
+0.16%-3.80%-53.59%-13.29% 69.5B
+3.67%+2.10%+19.46%-2.78% 49.68B
+0.97%+0.60%-23.33%-33.14% 45.26B
-0.80%-4.33%+8.90%+7.00% 36.88B
+1.73%-3.18%+3.31%+33.48% 35.13B
-1.52%-3.12%-12.23%-18.69% 29.46B
+0.74%-1.32%-22.78%-11.27% 27.84B
Average +0.60%-0.79%-9.14%-2.55% 68.59B
Weighted average by Cap. +0.55%-0.49%-6.76%-0.01%

Financials

2026 *2027 *
Net sales 26.13B 22.52B 20.72B 19.44B 36.52B 2,469B 36.88B 245B 95.7B 1,209B 98.04B 95.96B 4,184B 28.56B 24.62B 22.66B 21.25B 39.93B 2,699B 40.32B 268B 105B 1,322B 107B 105B 4,574B
Net income 4.38B 3.78B 3.48B 3.26B 6.13B 414B 6.19B 41.12B 16.06B 203B 16.45B 16.11B 702B 5.53B 4.77B 4.39B 4.11B 7.73B 523B 7.81B 51.86B 20.26B 256B 20.75B 20.31B 886B
Net Debt 9.02B 7.78B 7.16B 6.71B 12.61B 853B 12.74B 84.62B 33.05B 418B 33.86B 33.15B 1,445B 4.92B 4.24B 3.91B 3.66B 6.88B 465B 6.95B 46.18B 18.04B 228B 18.48B 18.09B 789B
Logo DANAHER
Danaher Corporation is an industrial and technologic group organized around three families of products: - diagnostic equipment (40.5% of net sales); - life sciences equipment (29.8%); - biotechnology equipment (29.7%): ranging from basic biological research to the development and manufacturing of vaccines, biological drugs, cell and gene therapies, and new technologies such as mRNA. Net sales are distributed geographically as follows: the United States (40.6%), China (10.7%) and other (48.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!